Progressive neuroblastoma Innovation and Novel Therapeutic Strategies Pediatric and Adolescent Medicine Series, Vol. Vol. 20

Neuroblastoma is a tumor derived from the sympathetic nervous system.

It is the most common extracranial solid tumor occurring in children and

exhibits a marked variability in outcome when the disease is categorized

by clinical (e.g. age or stage) and biologic characteristics. This book gives

an introduction into the clinical features of progressive neuroblastoma

and focuses on molecular-targeted therapies and immunotherapies of

this disease.

It has become increasingly clear that MYCN (v-myc avian myelocytomatosis

viral oncogene neuroblastoma derived homolog) holds a key position

in neuroblastic transformation and gene expression in normal and

transformed cells. In the 14 chapters important topics such as genomic

alterations in neuroblastoma and strategies for indirect molecular targeting

of MYCN are discussed. Two chapters, for example, review apoptotic

pathways and proapoptotic molecular targets in neuroblastoma, one

focusing on the p53 pathway and the other on the extrinsic and intrinsic

pathways of apoptosis. Other chapters cover topics related to immunology

in neuroblastoma, such as immune regulation in neuroblastoma,

immunotherapy related to passive and active vaccination approaches

and additional immunotherapy in the treatment of progressive disease.

This volume is essential reading for all clinicians and basic researchers

who are involved in delivering health care to patients with progressive

neuroblastoma.

Preface: Christiansen, H.; Christiansen, N.M.

Clinical Introduction

• Clinical Features of Progressive Neuroblastoma: Simon, T.

Genomic Alterations

• DNA Copy Number Changes and Beyond: Fieuw, A.; Schulte, J.H.; De Preter, K.; Speleman, F.

• Genomic Alterations and Abnormal Cell Cycle in High-Risk Neuroblastoma: Capasso, M.; Sidarovich, V.; Quattrone, A.; Tonini, G.P.

Targeting MYCN

• MYCN and MicroRNAs: Althoff, K.; Schulte, J.H.

• MYCN and Its Posttranslational Regulation in Neuroblastoma: Otto, T.

Apoptosis and Angioneogenesis

• Neuroblastoma and the p53 Pathway: Chen, L.; Tweddle, D.A.

• Targeting Cell Death Pathways in Neuroblastoma: Fulda, S.

• Neuroblastoma and Angiogenesis: Rössler, J.

Molecular-Targeted Therapy Studies

• The Role of the Anaplastic Lymphoma Kinase Receptor in Neuroblastoma: Yeung, C.M.; George, R.E.

• Molecular-Targeted Therapy in Refractory or Relapsed Neuroblastoma: Corbacioglu, S.

Immunology

• Immune Regulation in Neuroblastoma: Fest, S.; Starke, S.

• Approaches to Passive and Active Vaccination against Neuroblastoma: Lode, H.N.

• Role of Cell Therapy in Neuroblastoma: Bremm, M.; Brehm, C.; Huenecke, S.; Rettinger, E.; Bader, P.

Minimal Residual Disease

• Minimal Residual Disease in Neuroblastoma: Weber, A.

• Author Index

• Subject Index

Oncology; Pediatrics; Genetics, Immunology, Neurology, Neuroendocrinology, Neurosurgery